Study of XW003 for obesity with sleep apnea on CPAP therapy
Part of Brain & nervous system, Hormones & metabolism, Lungs & breathing clinical trials.
This trial tests an investigational drug called XW003 to see if it helps people with obesity and obstructive sleep apnea who are already using a positive airway pressure (PAP) machine, like CPAP. It aims to improve weight loss and sleep apnea symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a body mass index (BMI) of 28 or higher.
- You have moderate to severe obstructive sleep apnea, confirmed by a sleep study showing at least 15 breathing pauses per hour.
- You have been using a PAP machine for at least 3 months and plan to continue during the study.
- You have tried to lose weight through diet at least once without lasting success.
- You do not have diabetes or pre-diabetes that requires medication.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational weekly injection called XW003 for weight loss in people who have obesity and moderate-to-severe sleep apnea but do not use a CPAP machine. It aims to see if the drug can help with weight loss and improve sleep apnea without the need for a breathing machine.
This study tests whether a new injectable medicine called NNC0487-0111 helps people with excess weight and moderate-to-severe obstructive sleep apnea (a condition where breathing stops repeatedly during sleep) lose weight and improve their sleep apnea—without needing a CPAP machine. The goal is to see if better weight loss can reduce sleep apnea symptoms.
This study tests a new injectable medicine (NNC0487-0111) to help people lose weight and improve obstructive sleep apnea (a breathing condition during sleep). You must already be using a CPAP machine (positive airway pressure device) for your sleep apnea.
This study tests an investigational medication called eloralintide to see if it can improve sleep apnea in people who are overweight or have obesity. You will receive either the study drug or a placebo (inactive shot), and your sleep and weight will be monitored over time.
This study tests an investigational medication (IBI362) to see if it can improve sleep apnea in people with obesity. You might qualify if you have moderate to severe sleep apnea and a BMI of 28 or higher, whether or not you currently use a CPAP machine.
This study tests two new experimental medications designed to help adults lose weight and improve weight-related health conditions like high blood pressure and sleep apnea. Participants will take one of these medications to see if it's safe and effective.
Hear when a new Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.